Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer
By Ernest L. Mazzaferri, R. Kloos. 2001
1,326 citations recorded by the source corpus.
Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Surgery
View Paper: https://www.semanticscholar.org/paper/6d4f89e3746f4d677d1d0714ac01eeb1275baf91
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrinology, Diabetes and Metabolism
In Genetics
In Surgery
Citations in the corpus
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer (2009, neutral): “Recent studies have reported primarily on patients with Tg levels after T4 withdrawal of 10 ng=mL or higher, and it has been suggested that a corresponding level after rhTSH stimulation would be 5 ng=mL (308,374,416,418,424).”
- A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. (2003, background): “The frequency of lung metastases in patients empirically treated with (131)I for a high serum Tg and negative DxWBS ranges from nearly 6% in one study (44) to 9% in another (1), and from 35–55% of selected patients in two other studies (45, 46).”
- Papillary microcarcinoma of the thyroid—Prognostic significance of lymph node metastasis and multifocality (2003, background): “For patients with PTC, LN metastasis is a common finding at presentation, varying from 50% to 80%.(46) To date, the recommendation for LN surgery is not unified.”
- Estimating Risk of Recurrence in Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation: Using Response to Therapy Variables to Modify the Initial Risk Estimates Predicted by the New American Thyroid Association Staging System (2010, background): “entirely due to young patients with distant metastases at diagnosis (M1) who are very unlikely to die of thyroid cancer, but quite likely to have persistent disease during the first several years of follow-up (26).”
- Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. (2006, background): “5) Lung and bone 7 (5) 40 (24) 34 (26) Unusual sites 1 (1) 11 (7) 7 (5) Extent of metastases (%) Category 1 80 (63) 17 (10) 7 (5) Category 2 37 (29) 58 (35) 34 (26) Category 3 10 (8) 93 (55) 91 (69) Histology (%) Pap 96 (77) 41 (24.”
- Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients (2002, background): “Indeed, one might have the impression from recent literature that the criterion for “cure” of PTC during the present era may require demonstration of an undetectable serum Tg on thyroxine suppressive therapy that will not be significantly stimulated by either rhTSH or hormone withdrawal [12, 13, 15,”
- Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce (2006, neutral): “Some patients will have a reduction in tumor burden with additional treatments that may offer a survival or palliative benefit (204,210–212).”